Detection of karyotypic clonal abnormalities are prognostically useful in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS), but cytogenetic methods are not sensitive enough to detect low numbers of residual leukemic cells in patients who have achieved complete remission (CR). Fluorescence in situ hybridization (FISH) and fluorescence activated cell sorting (FACS) were used to investigate the frequency and presence of minimal residual disease (MRD) in AML and MDS patients (n = 28) with monosomy of chromosomes 7, 17 and 18 and trisomy of chromosomes 6, 8, 9 and 10 in CR. MRD was detected in all patients with monosomy 7 (n = 10) and followed by relapse in eight patients after 4.8 ± 3.1 months. In contrast, persistent leukemic cells occurred in 11/12 patients with trisomy 8, but only three of them relapsed after 7.7 ± 4.0 months. Cox regression analysis showed that cytogenetic class and levels of clonal cells at CR were related to time to relapse (P = 0.001). The level of MRD identified patients at high and low risk of relapse. High absolute levels of proliferating residual leukemic cells correlated with monosomy 7 and high risk of relapse.
Introduction
Improvements in chemotherapy of acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) have resulted in high complete remission (CR) rates even in patients with unfavorable cytogenetics. [1] [2] [3] [4] [5] [6] [7] [8] However, the majority of patients, especially those with chromosomal abnormalities like as −5, 5q−, −7, 7q−, +8, 11q23 and t(9;22) relapse. 1, 4, [9] [10] [11] [12] [13] [14] Therefore detection and quantitation of minimal residual disease (MRD) and a better knowledge of proliferative characteristics of residual leukemic cells would be important for developing new treatment strategies. Morphological criteria do not allow one to identify less than 5% leukemic cells. 15 Many techniques such as cytogenetics, [16] [17] [18] [19] [20] [21] colony assays in acute lymphoblastic leukemia, 22 DNA flow cytometry, 23 two-or three-color immunofluorescence, [24] [25] [26] [27] [28] [29] [30] polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) have been used to detect MRD in patients in clinical remission. [31] [32] [33] [34] [35] [36] [37] [38] [39] Chromosomal abnormalities are detectable in the leukemic cells of most patients with AML and MDS, but cytogenetic evaluation depends on adequate numbers of metaphases of sufficient quality. 40, 41 Molecular cytogenetics using FISH is a potentially more sensitive and proliferation-independent method than cytogenetics, which allows the scoring of a large number of cells, and should therefore be superior in the detection of residual leukemic cells.
Correspondence: H Engel, Department of Hematology and Oncology, Medical School of Hannover, Carl-Neuberg-Strasse 1, 30632 Hannover, Germany; Fax: 49 511 532 3611 Received 6 July 1998; accepted 3 December 1998 This study was designed to investigate the frequency and presence of MRD in patients with AML and MDS and abnormalities of chromosomes 6, 7, 8, 9, 10, 17 and 18 in complete remission. FISH was used in bone marrow (BM) samples of 28 patients (16 AML, 12 MDS) at the time of CR to study MRD. We also determined the proliferative activity of residual leukemic cells by applying FISH to cells labeled with bromodeoxyuridine (BUdR). In addition bone marrow progenitor cells were separated by fluorescence activated cell sorting (FACS) into different subpopulations based on their immunophenotype at diagnosis and then analyzed by FISH. We investigated the clinical potential of this approach in the detection of low levels of leukemic cells and the prediction of recurrent disease.
Materials and methods

Patients and treatment
In this study we included 28 adult patients (20 male, 8 female) with a median age of 59.5 years (range, admitted to the Leukemia Service in the Department of Hematology at the University of Texas MD Anderson Cancer Center. Sixteen had the diagnosis of AML: one trisomy 6, five monosomy 7, eight trisomy 8, one trisomy 9, and one monosomy 17; 12 had MDS: five monosomy 7, four trisomy 8, one trisomy 10, one monosomy 17, and one monosomy 18 ( Table 1) . The karyotypes at diagnosis were determined by conventional cytogenetic methods. The median age of patients in each chromosomally abnormal group was 55 years (range, 32-81) for monosomy 7, 63 years (range, 22-71) for trisomy 8, and 60.5 years (range, 34-81) for patients with other abnormalities.
For induction of remission, patients were treated with the following protocols: 4, 8, 14, 42 DM 93-048/049 (fludarabine, Ara-C, G-CSF, idarubicin (n = 15)); DM 92-019 (G-CSF, fludarabine, Ara-C (n = 11)); DM 91-026 (interleukin-3, idarubicin, Ara-C (n = 1)) and DM 92-048 (cyclophosphamide, doxorubicin, vincristine, dexamethasone, G-CSF, methotrexate, Ara-C (n = 1)). Twenty-one patients had de novo disease (13 AML, 8 MDS), one patient with AML was in first relapse and six patients (2 AML, 4 MDS) had been previously treated for different types of solid tumors. Post-induction therapy of patients on the DM 93-048/049 protocol was given as follows: (a) fludarabine, Ara-C, G-CSF, idarubicin (n = 5); (b) etoposide, mitoxantrone, G-CSF followed by (c) etoposide, cyclophosphamide, G-CSF (n = 5); (d) idarubicin, Ara-C, G-CSF (n = 5). Patients on the DM 92-019 protocol received as post-induction therapy fludarabine, Ara-C and G-CSF.
Bone marrow samples were obtained following informed consent at the time of diagnosis and complete remission (days 21 or 28). Cells were FACS-sorted (12/28 samples) at CR based on the coexpression of certain antigens at the time of diag- To detect different hematopoietic cell populations (12/28 samples), the following directly labeled antibodies were used: Leu-M1/CD15, Leu-M7/CD13, HPCA-2/CD34, Leu-M9/CD33, Leu-4/CD3 (Becton Dickinson, San Jose, CA, USA). 10 l of a phycoerythrin (PE)-or fluorescein-isothiocyanate (FITC) conjugated antibody were added to 10 6 cells in 100 l PBS, containing 1% bovine serum. Appropriate isotype controls were used for setting amplification and compensation of the flow cytometer. After an incubation time of 30 min on ice, cells were washed twice and resuspended in 500 l PBS.
Cell sorting was performed with FACStar PLUS or FACS Vantage cell sorters (Becton Dickinson) equipped with argon ion lasers (Spectra Physics, San Jose, CA, USA) operated at 488 nm and 100 mW. Green (FITC) and red (PE) fluorescence were detected using 530/30 nm and 585/40 nm bandpass filters. Sheath fluid contained unmodified Isotone II (Coulter, Hialeah, FL, USA), and the sheath pressure was adjusted to 10 PSI. One thousand cells were sorted directly on a premarked clean slide using counter mode and the tube carrier for the Macrosort to get a horizontal layer for the slide. Before sorting, 15 l of a solution of 3% BSA in PBS (freshly prepared every 2 weeks) was applied in a drop on to the premarked area of the slide. Slides without BUdR-labeled cells were air dried overnight, fixed with 3:1 methanol:glacial acetic acid, and stored at −20°C until hybridization. BUdR-labeled samples were dried under vacuum and fixed immediately.
Fluorescence in situ hybridization
After Ficoll separation cells were fixed with 3:1 methanol:glacial acetic acid, and stored at −20°C until hybridization. Sorted and unsorted slides were incubated at room temperature in 3:1 methanol:glacial acetic acid for 15 min and in 0.1 n HCl with 0.05% Triton X-100 for 15 min and then washed six times: once for 2 min in 2× saline sodium citrate (SSC), once in PBS, once in PBS with 1% formaldehyde for 5 min, twice for 2 min with PBS, and finally once with 2× SSC. Slides were denatured in 70% formamide in 2× SCC at 70°C for 2-4 min, dehydrated in a 70%, 85%, 100% ethanol series, and air dried.
Biotin-labeled alpha-satellite probes specific for chromosome 7 and 8 (probe D7Z1, D8Z1; Oncor, Gaithersburg, MD, USA) or directly conjugated centromeric probes (CEP) from Vysis (Naperville, IL, USA) were used for interphase FISH (CEP 7 and 18 conjugated to Spectrum Green and CEP 6, 7, 8, 9, 10, 17 and 18 conjugated to Spectrum Orange). 1 l of each probe was diluted to give a 10 l hybridization mixture consisting of 50% formamide (BRL, Gaithersburg, MD, USA) 2× SSC, 10% dextran sulfate (Sigma), and 100 g/ml low molecular weight DNA (salmon or herring sperm, Sigma). Probe DNA was denatured for 5 min at 70°C and applied to each slide. Hybridization was performed overnight at 37°C in a humidified chamber.
Unhybridized probe was washed off by a series of three post-hybridization washes in 50% formamide in 2× SSC at 45°C each for 10 min, followed by one 10-min wash in 2× SSC and one 5-min wash in 2× SSC/0.1% NP-40 at 37°C. The biotinylated probe was detected by avidin DN (Vector Laboratories) conjugated to rhodamine (5 l/ml in 4 × SSC/0.1% NP40/5% nonfat dried milk). The fluorescence signal was amplified using biotinylated anti-avidin (5 g/ml) and another layer of avidin Texas Red. Up to two amplifications were performed. The nuclei were counterstained with diamino-2-phenylindole dihydrochloride (DAPI, 0.2 m in 90% glycerol/10% PBS, pH 8 
Statistical analysis
Remission duration data were analyzed using the standard Kaplan-Meier survival estimate, taking into account data censored due to limited follow-up. Dependence of the time to relapse on covariates, including the level of residual leukemic cells, S-phase, and cytogenetics, were analyzed using the stepwise Cox regression (proportional hazard) method. Other statistical comparisons were carried out using the one-way analysis of variance and other standard methods. The SPSS statistical package was employed for these analyses as well as to generate descriptive statistics of the data.
Results
Controls and sensitivity
Bone marrow samples from normal individuals were used to determine the background for each chromosome probe (n = 5). We studied unsorted mononuclear, CD13 + , and CD34 + FACS-sorted cells. The incidence of cells with one hybridization signal for chromosomes 7, 17, 18 and three signals for chromosomes 6, 8, 9, 10 is listed in Table 2 and was considered proof of monosomy or trisomy if the frequency was greater than the mean plus two standard deviations (s.d.) of normal BM controls.
Dilution experiments were performed to determine the sensitivity of FISH after FACS sorting. AML cells of a cell line with 97.0% trisomy 8 and a phenotype of CD5
+ were sorted into normal peripheral blood cells (10.0%, 1.0%, 0.5%, 0.1% and 0.05% AML). As expected, FISH failed to detect leukemic cells in unsorted samples at the 1.0% level. In CD5 + /CD13 + FACS-sorted cells we were able to identify 11.0% of trisomy 8 cells in a dilution containing as few as 0.05% AML cells (Table 3) .
Minimal residual disease in patients with AML or MDS in complete remission
We studied BM samples from 28 adult patients (12 with trisomy 8, 10 with monosomy 7 and six with other cytogenetic Figure 1) . Four of 11 patients had less than 3% of residual leukemic cells. There was no statistical difference between AML and MDS with regard to the level of clonal cells (P = 0.086). FISH detected residual cells above background level in unsorted cells of nine patients. In two patients (Nos 7 and 15) clonal cells were found only after analysis of CD13
+ cells. Three of 12 patients relapsed (2 AML, 1 MDS) with a median remission duration of 7 months (range, 4-12), and nine patients are still in clinical remission with a median follow-up of 18 months (range 4-29). Standard cytogenetic analyses at CR were carried out in two of three patients who relapsed and all of them had diploid metaphases.
Residual leukemic cells were detected in all 10 patients with monosomy 7 (5 AML, 5 MDS) at levels of 0.04% to 13.9% (median 7.6%, mean ± s.d.: 8.0% ± 5.0%) of nucleated BM cells (Table 4 , Figure 2 ). There was no statistical differences between AML and MDS with regard to the level of clonal cells (P = 0.086). Standard cytogenetic analysis at CR performed in six of 10 patients identified one metaphase in two cases and three metaphases in another case with the abnormal clone. 
/CD13
− stem cell compartment (Table 4) . Eight of 10 patients relapsed (4 AML, 4 MDS), with a median remission duration of 4.8 months (range, 1-11), one patient with MDS died after 1 month in CR, and one patient with AML is still in clinical remission with a follow-up of 6.5 months.
We also studied BM samples from six adult patients (Table  4 , Figure 3 ) with other cytogenetic abnormalities (three AML (trisomy 6, trisomy 9 and monosomy 18) and three MDS (trisomy 10, monosomy 17 and monosomy 18)). Residual disease was detected in all six patients at levels of 0.03% to 10.3% (median 4.2%, mean ± s.d.: 4.3% ± 3.4%) of nucleated BM cells. In two patients with AML (Nos 3 and 13) clonal cells were found only after enrichment of CD13 + /CD34 + or CD3 + /CD33 + cells. The levels of abnormal cells were higher in patients with MDS (median 3.7%, mean ± s.d.: 6.3% ± 3.5%) than in patients with AML (median 2.1%, mean ± s.d.: 2.3 ± 2.4%; P = 0.018). The significance of this finding is limited by small sample size. Three of six patients relapsed (one AML, two MDS) after a median remission duration of 5 months (range, 4-7), two patients are still in clinical remission (one patient had less than 3% of residual leukemic cells) with follow-up of 10 and 14 months, and one patient died after 5 months in CR. Standard cytogenetic analyses at CR, performed in two of the three patients who relapsed, were negative.
Detection of proliferating residual leukemia cells
The proliferation of residual leukemic cells was determined by incorporation of BUdR. In four of six patients with trisomy 8 studied, proliferating residual leukemic cells were not found in the unsorted marrow samples ( Table 4) . The other two patients showed trisomy 8 cells with an S-phase of 22.7% 
/CD13
− cells (S-phase 13.8% and 75.0%), respectively (Table 4) .
Bone marrow samples from patients with other cytogenetic abnormalities (5/6 studied) showed also proliferating leukemic cells (Table 4 ; median S-phase: 27.8%, range: 4.2% to 38.7%, mean ± s.d.: 19.7% ± 18.1%).
Cox regression analysis and Kaplan-Meier survival estimate
The two main questions we asked were: (1) whether the level of abnormal cells independently affects remission duration; and (2) whether the cytogenetic group is related to the time to relapse. The Cox regression analysis (log linear model) presented in Table 5 provides answers to both questions. The cytogenetic categories (monosomy 7, trisomy 8 and others) were coded using two indicator variables (called cytogenetics 1 and 2), as explained in Table 5 . The level of abnormal cells was treated as a continuous variable.
The model that included both cytogenetics and level of abnormal cells (all three variables) provided an excellent fit at P = 0.001. The chromosomal abnormality alone still provided a very good fit (P = 0.003), as did the level of abnormal cells alone (P = 0.018).
The level of abnormal cells correlated with cytogenetics. However, it still constituted an independent prognostic factor, as is demonstrated by decrease in goodness of fit when the level of clonal cells was removed from the complete model. The chi-square score was 3.93, which is significant at P = 0.048.
The Kaplan-Meier curve (Figure 4) illustrates the prognostic importance of the level of residual leukemic cells at CR. Patients with levels of abnormal cells less than 3% had a longer remission duration (P = 0.012). There was no statisti- MRD levels in AML/MDS with monosomy 7 at CR. All patients show levels of residual leukemic cells above 3% at CR and 8/10 relapsed.
Figure 3
MRD levels in AML/MDS with other cytogenetic abnormalities at CR. Five of 6 patients had MRD levels above 3% at CR and three of them relapsed. One patient with less than 3% of residual leukemic cells is still in clinical remission. cally significant difference between AML and MDS patients (P = 0.976).
Discussion
Quantitation of residual disease in AML and MDS patients is important to directly assess the efficacy of induction therapy. Patients with AML/MDS can be separated into favorable (inv16, t(8;21), t(15;17)) and unfavorable cytogenetic categories (+8, −5, 5q−, −7, 7q−, 11q23, Philadelphia-positive). This classification has major prognostic impact. Patients with the nonrandom changes t(8;21), t(15;17) and abnormalities of 16q have a much better prognosis than patients with trisomy 8, monosomy 5 or 7.
1-4,9-14 The position of patients with trisomy 8 abnormalities is not clear-cut. The United Kingdom Medical Research Council (MRC) Group drew attention to the fact that the presence of trisomy 8 did not modify the outcome, whether associated with favorable or poor risk abnormalities. Only patients with sole trisomy 8 abnormality fell into an intermediate prognostic group. [43] [44] [45] When patients achieve clinical CR status, the frequency of leukemic cells is usually below the detection limit of cytogenetic analysis. The number of leukemic blast cells detected morphologically is low (by definition Ͻ5.0%), and cells may not be dividing. Therefore other methods with higher sensitivity are needed for detecting MRD. PCR is available only for t(15;17), t(8;21) and inversion 16. [34] [35] [36] [37] [38] [46] [47] [48] [49] The aberrant expression of myeloid and lymphoid or early and late myeloid antigens has been used to identify MRD by flow cytome- try. 10, 24, [26] [27] [28] [29] [30] [31] [50] [51] [52] However, steady-state normal hematopoiesis should be different from regeneration hematopoiesis after chemotherapy and the expression and coexpression of differentiation antigens has not been systematically studied in this situation.
In this study, we used molecular cytogenetics of FACSsorted progenitor cells to detect residual disease at the single cell level in patients with AML and MDS considered to be in CR. Alpha-satellite DNA probes specific for chromosomes 6, 7, 8, 9, 10, 17 , and 18 were used to detect numerical abnormalities in interphase nuclei. Dilution experiments showed that FISH alone was not particularly sensitive in detecting low numbers of leukemic cells with trisomy 8 (detection limit Figure 4 Prognostic importance of MRD detected by FISH in AML/MDS at CR. Kaplan-Meier curve showing the probability of relapse. Patients with an absolute level of residual leukemic cells Ͻ3% had a longer remission duration (P = 0.012).
1.0%). To improve sensitivity we used FACS-sorting to isolate rare subpopulations of BM progenitor cells, which were then analyzed by FISH. In the population of cells coexpressing CD34 and CD13 or CD3 and CD33 the average relative number of clonally abnormal cells, as determined by molecular cytogenetics was 4.7% to 47.2%.
By using this method we were able to detect residual leukemic cells in 27 of 28 patients with AML or MDS just after induction chemotherapy induced CR. In five patients clonal cells were found only after enrichment of CD13
+ cells. The detection of persistent leukemic cells in patients in CR was followed by relapse in eight of 10 patients with monosomy 7 after 4.8 ± 3.1 months. In contrast, we were able to detect residual cells in 11 of 12 patients with trisomy 8, but only three of them relapsed. FISH analysis showed significantly higher levels of residual leukemic cells in patients with monosomy 7 (8.0% ± 5.0%) as compared to patients with trisomy 8 (3.5% ± 3.1%) or other cytogenetic abnormalities (4.3% ± 3.5%; P = 0.011, Figure 5 ). BUdR incorporation studies demonstrated higher proliferative activity in the leukemic cells of patients with monosomy 7 (S-phase 19.4% ± 16.6%) than in patients with trisomy 8 (no proliferation detectable in four of six samples; two samples with an S-phase of 22 Statistical analysis by Cox regression showed that cytogenetics and levels of clonal cells at CR were related to the time to relapse (P = 0.001), with chromosomal abnormality being the single most important factor (P = 0.003). However, the level of residual leukemic cells independently affected
Figure 5
Absolute levels of MRD in patients with AML/MDS and monosomy 7, trisomy 8 and other cytogenetic abnormalities at CR (mean ± s.e.m.). FISH showed higher levels of abnormal cells in patients with monosomy 7 than in patients with trisomy 8 or other cytogenetic abnormalities (P = 0.011).
remission duration (P = 0.018) and was even significant (P = 0.048) after it was adjusted for cytogenetic classification. Hence, the level of clonal cells remains significant despite the fact that the number of residual cells correlates with cytogenetics. Kaplan-Meier analysis (Figure 4) illustrates the prognostic importance of the level of residual leukemic cells at CR. Patients with levels of abnormal cells at CR less than 3% had longer remission durations than those with greater than 3% (P = 0.012). There was no significant difference between AML and MDS patients with regard to the level of clonal cells in each chromosomally abnormal group It indeed seems likely that patients with a sustained population containing Ͻ3% abnormal cells have a disease with a very prolonged doubling time, a characteristic shared by the so-called good prognostic group. However, it is clear that there is heterogeneity in all prognostic groups and there are subtleties which have not been defined.
Our studies demonstrated a poorer prognosis for patients with monosomy 7. Eight of 10 patients relapsed after a median remission duration of 4.8 months, whereas patients with trisomy 8 relapsed after a median remission duration of 9 months (3/12), and nine patients remained in clinical remission for a median of 18 months. We could demonstrate a correlation between absolute levels of clonal cells, proliferation rate, and shorter time to relapse in patients with monosomy 7.
These findings lead to several intriguing questions and conclusions: (1) What factors regulate the different sensitivities of cells with monosomy 7 and trisomy 8 to the same induction therapy? Could differences in MDR1, MRP, p180 (LRP56), bcl-2, c-myc, p53 and other factors affecting chemotherapeutic sensitivity be responsible? 53, 54 The significantly improved rate of complete remissions for these patients (from 34% with FAMP/Ara-C to 59% with G-CSF/FAMP/Ara-C) points to cytokine sensitive processes. 4 (2) The surprisingly high levels of leukemic cells at CR suggest that leukemic cells are able to differentiate. 55, 56 (3) Is the ability to proliferate, the inability to continue to differentiate, or the loss of apoptotic potential responsible for relapse? The surprisingly high levels of proliferating cells at CR suggest the removal of inhibitory factors and would be expected at the lower end of a Gompertzian growth curve. (4) The fact that remissions cannot be maintained with the prolonged post-induction therapy given in this trial, also points to differences in resistance mechanisms operative at diagnosis, when a 2 log cell kill can be achieved, and at MRD, when this is not the case. It would follow that studies of drug resistance mechanisms at diagnosis would provide little insight into the mechanisms leading to relapse and that efforts to better characterize residual leukemic cells should be intensified. (5) The long clonal remissions observed in patients with trisomy 8 resemble those detected by PCR or FISH in AML patients with t(8;21) or inversion 16. 38,49,57,58 The low or absent proliferation in these patients of residual leukemic cells could point to cell cycle events, and not to the ability to undergo differentiation or programmed cell death as the dominant mechanism.
The current methods of detecting MRD are only in their early stages of development and may establish the basis for further work, but it still gives an incomplete answer to the prevention of relapse. Guidelines need to be established as to what percentage of abnormal cells is significant and which time points after CR are predictable for relapse. However, a follow-up during complete remission is necessary to provide valuable prognostic information. 59 Studies to quantitate and characterize residual disease in patients with other cytogenetic abnormalities are under way. The ability to physically separate and analyze rare leukemic cells could now provide clues to novel therapeutic strategies that are urgently needed. Absent or low unstable levels of residual leukemic cells or high and rising levels could help in deciding which patients should receive autologous or allogeneic bone marrow transplants.
